Related Experiment Video
Updated: May 28, 2026
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
STK11 as an Emerging Biomarker in Non-Small Cell Lung Cancer
Amit A Kulkarni1, Adam Rock2, Matthew Lee2
1Department of Medical Oncology and Therapeutics Research, City of Hope Phoenix, Goodyear, AZ 85338, USA.
Abstract:
Immune checkpoint inhibitors (ICIs) have transformed non-small cell lung cancer (NSCLC) treatment; however, durable responses occur in only a subset of patients, underscoring the need for robust predictive biomarkers. Serine/threonine kinase 11 (STK11) is an emerging biomarker that portends poor prognosis and predicts therapeutic resistance. Loss of STK11 disrupts AMPK signaling, leading to unchecked mTOR activation, metabolic reprogramming, angiogenesis, and epithelial-mesenchymal transition, fostering tumor progression and immune evasion. STK11 mutations frequently co-occur with KRAS and KEAP1 alterations, exhibit low PD-L1 expression, an immunosuppressive tumor microenvironment that leads to the development of PD-1/PD-L1 resistance. Clinical studies consistently demonstrate inferior outcomes with ICIs in STK11-mutant NSCLC, particularly in the presence of KRAS and KEAP1 co-mutations. Dual checkpoint inhibition combining PD-1/PD-L1 and CTLA-4 blockade shows promise in overcoming resistance, results remain inconsistent, and prospective trials are ongoing. Beyond immunotherapy, STK11 mutations confer poor outcomes across targeted therapies, including KRAS G12C inhibitors, with KEAP1 co-mutation serving as a strong negative predictor of efficacy. In this review we present an overview of STK11 function and its role in tumor biology, highlight the prognostic and predictive potential of STK11 mutations in the context of NSCLC treatment and summarize the emerging treatment strategies.
Insights
Serine/threonine kinase 11 (STK11) mutations in non-small cell lung cancer (NSCLC) predict poor response to immune checkpoint inhibitors (ICIs). Understanding STK11's role is crucial for developing effective NSCLC treatments.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genomics
Background:
- Immune checkpoint inhibitors (ICIs) have revolutionized non-small cell lung cancer (NSCLC) therapy, but only a fraction of patients achieve durable responses.
- Serine/threonine kinase 11 (STK11) mutations are emerging as critical biomarkers, associated with poor prognosis and resistance to ICIs in NSCLC.
Purpose of the Study:
- To review the function of STK11 in tumor biology.
- To highlight the prognostic and predictive significance of STK11 mutations in NSCLC treatment.
- To summarize emerging therapeutic strategies for STK11-mutant NSCLC.
Main Methods:
- Literature review of STK11 function, mutation co-occurrence, and clinical outcomes in NSCLC.
- Analysis of STK11's impact on tumor metabolism, angiogenesis, and immune evasion.
- Synthesis of data on ICI and targeted therapy efficacy in STK11-mutant NSCLC.
Main Results:
- STK11 loss disrupts AMPK/mTOR signaling, promoting tumor progression and immune evasion.
- STK11 mutations frequently co-occur with KRAS and KEAP1 alterations, correlating with low PD-L1 expression and resistance to PD-1/PD-L1 therapy.
- Inferior outcomes are consistently observed with ICIs and KRAS G12C inhibitors in STK11-mutant NSCLC, especially with KEAP1 co-mutations.
Conclusions:
- STK11 mutations are significant negative predictors of response to current immunotherapies and targeted therapies in NSCLC.
- Dual checkpoint inhibition shows potential but requires further investigation.
- Further research into novel treatment strategies is essential for improving outcomes in STK11-mutant NSCLC.
